Literature DB >> 11398896

The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.

S A Grumett, V R Archer, R Midgley, P Mulholland, S Nicum, L Blewitt, D J Kerr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11398896     DOI： 10.1023/a:1011106917263

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.

Authors:  R-D Hofheinz; A Willer; A Weisser; U Gnad; S Saussele; S Kreil; J T Hartmann; R Hehlmann; A Hochhaus
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

2.  Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.

Authors:  J T Hartmann; K Oechsle; D Quietzsch; A Wein; R D Hofheinz; F Honecker; O Nehls; C-H Köhne; G Käfer; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.